46 results about "Heparin-DHE" patented technology

The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and / or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention.

Novel conjugates of glycosaminoglycans, particularly heparin and dermatan sulfate, and amine containing species and therapeutic uses thereof are described. In particular, mild methods of conjugating heparins to proteins, such as antithrombin III and heparin cofactor II, which provide covalent conjugates which retain maximal biological activity are described. Uses of these conjugates to prevent thrombogenesis, in particular in lung airways, such as found in infant and adult respiratory distress syndrome, and on surfaces in contact with blood are also described.

The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to treatment or prevention of ischemic events in patients with cardiovascular disease. The present invention is particularly useful for patients having or being at increased risk of development of an ischemic event such as an acute myocardial infarction and / or no-reflow phenomena and / or ischemia-reperfusion injury by administration of agent(s) modulating and / or preserving endothelial integrity. The compounds may be administered in combination with standard treatment of acute cardiovascular ischemic events such as Platelet inhibitors such as aspirin (ASA), Thienopyridins, GPIIb / IIIa inhibitors), Parenteral anticoagulants such as unfractioned heparin (UFH), bivalirudin, enoxaparin, and fondaparinux, Verapamil, Adenosine, Sodium nitroprusside, Nitroglycerin, Epinephrine, Beta-blockers and surgical methods such as percutaneous coronary intervention (PCI), PCI with thrombus aspiration, PCI with stents.

A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a hydrophilic polymer, a non-fouling polymer, or combinations thereof. The medical device can be implanted in a human being for the treatment of a disease such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.

The invention relates to a bioactive hydrogel as a hybrid material of heparin and star-branched polyethylene glycol with functionalized end groups, wherein the heparin is bound directly by reaction of the carboxyl groups activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimides / N-hydroxysulfosuccinimide (EDC / s-NHS) with the terminal amino groups of the polyethylene glycol covalently by amide bonds.

The invention discloses a detection method for heparin content. The detection method comprises the steps of mixing a sample to be tested with an FXa activity detection reagent by a developing substrate method to obtain a mixture, incubating the mixture, and detecting the signal intensity of a developing substrate; and finally calculating signal intensity and comparing the calculated signal intensity with a standard curve to obtain the heparin content of the sample to be tested, wherein the developing substrate is a developing substrate of an activated factor X (FXa) and is selected from any one of the following substrates of Benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide.HCl, CH3O-CO-D-CHA-Gly-Arg-p-nitroanilide.AcOH, Acetyl-D-Arg-Gly-Arg-p-nitroanilide.2HCl and 4-Nz-D-Arg-Gly-Arg-p-nitroanilide.2HCl. The detection method disclosed by the invention can be used for detecting general non-graded heparin, low-molecular-weight heparin and fondaparinux; furthermore, according to the detection method, the detection stability and the repetitiveness are high, the heparin content can be reflected accurately, the sensitivity and the accuracy are extremely high, and the optimal dosage range of the heparin can be found out quickly, so that a patient does not need to be detected for multiple times. Moreover, the detection method can be also used on an automatic instrument such as a coagulation analyzer or a biochemical analyzer, so that automation is realized, and clinical popularization and application can be assisted; the detection method has the characteristics of simplicity in operation, high sensitivity and high repetitiveness.

Enhanced extraction and assay of solubilized lipopolysaccharide antigens from bacteria such as Chlamydia by the use of a buffer containing an anionic polysaccharide, especially heparin, and surface active agent, especially CHAPS or CHAPSO.

The invention discloses a heparin content detection method. The heparin content detection method comprises the following steps of by a developing substrate method, mixing a sample to be detected and a FXa activity detection reagent, carrying out incubation, detecting signal intensity of the developing substrate, calculating signal intensity and comparing the signal intensity and a standard curve to obtain heparin content of the sample to be detected, wherein the developing substrate is a developing substrate of an activation factor X(FXa) and is selected from Benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide.HCl, CH3O-CO-D-CHA-Gly-Arg-p-nitroanilide.AcOH, Acetyl-D-Arg-Gly-Arg-p-nitroanilide.2HCl, and 4-Nz-D-Arg-Gly-Arg-p-nitroanilide.2HCl. The heparin content detection method can be used for detecting common unclassified heparin, low-molecular weight heparin and fondaparinux, has good detection stability and good repeatability, can accurately show heparin content, has high sensitivity and accuracy, can fast find the optimal dosage scope of heparin and is free of multitime detection on patients. The heparin content detection method can be used for automation apparatuses such as a hemagglutination analyzer or a biochemical analyzer, realizes automation, is conducive to clinical popularization use and has the characteristics of simple operation, high sensitivity and good repeatability.

The invention discloses a method for preparing a mesoporous silicon nanoparticle coating loaded with heparin and Cu<2+> on the surface of a biological material. The method comprises the steps of carrying out surface modification on mesoporous silicon nanoparticles to obtain amino-modified mesoporous silicon nanoparticles to load heparin and Cu<2+> into a mesoporous duct; modifying the surfaces of the nanoparticles by using albumin; and finally fixing the nanoparticles on the surface of the dopamine-modified biological material to obtain the mesoporous silicon nanoparticle coating loaded with the heparin and the Cu<2+>. Surface modification is carried out on a material or device implanted into a blood vessel by adopting the method, so that the loading capacity and the release behavior of the heparin and the Cu<2+> on the surface of the material can be effectively controlled, the material is endowed with good blood compatibility and regeneration of blood vessel endothelium can be significantly promoted, thereby effectively improving the biocompatibility and the implant success rate of the material.

Compositions and methods of employing compositions in flushing and coating medical devices are disclosed. The compositions include combinations of a chelating agent, anticoagulant, or antithrombotic agent, with a C4-C9 carboxylate antimicrobial agent, such as octanoic acid. Methods of using these compositions for coating a medical device and for inhibiting catheter infection are also disclosed. Particular combinations of the claimed combinations include, for example, octanoic acid or other C4-C9 carboxylate antimicrobial agent together with EDTA, EGTA, DTPA, heparin and / or hirudin in a pharmaceutically acceptable diluent.

The invention discloses a preparation method and application of cross-linked hydrogel for muscle stem cell culture, and belongs to the technical field of biological food materials. Chitosan, alginate, dextran and Ca<2+> are crosslinked through a physical crosslinking method to form double-network hydrogel with high mechanical strength, and then the hydrogel is coated with heparin and collagen through a dipping coating method, so that the hydrogel can immobilize growth factors and adhere to cells. Meanwhile, the extracted primary muscle stem cells are inoculated onto the hydrogel and cultured for 24 hours in a growth culture medium (79% of DMEM, 10% of FBS and 1% of double antibodies); and then the extracted primary muscle stem cells are cultured in an incubator with a differential medium (97% of DMEM, 2% of horse serum and 1% of double antibodies) for 7 days. By utilizing the hydrogel, the absorption of the muscle stem cells on nutrient substances can be enhanced, and the growth of the muscle stem cells is facilitated. The dual-network hydrogel has the potential to be used as a scaffold for muscle stem cell growth of stem cell culture meat.

Plaster for topical use having an analgesic activity and at the same time being able to re-absorb haematomas, comprising: a substrate layer; an adhesive layer in the form of a hydrogel matrix containing a pharmaceutically acceptable diclofenac salt, heparin or a heparinoid; a protective film which can be removed at the moment of use.

The present invention relates to novel heparin-nitroxide derivatives comprising heparin and at least two and more nitroxides / polynitroxide radicals that are covalently coupled to heparin by derivatisation of glycosaminoglycan carboxyl or amino groups. The heparin-nitroxide derivatives are useful as therapeutic or diagnostic agents. This invention further concerns novel methods for the production of the heparin-nitroxide agents, and methods of their uses for specifically targeting and labelling of biological vessels. The inventions also suggest the uses of the heparin-nitroxide derivatives for treatment of oxidative stress-mediated diseases. Furthermore, the heparin-nitroxide derivatives according to the present invention are in particular useful for electron paramagnetic resonance imaging (EPRI), for magnetic resonance imaging (MRI), and for preservation of biological transplants.

The invention relates to a composition of glycosaminoglycans for the treatment of diabetic foot ulcer, it specifically relates to low molecular weight heparins (LMWHs) and very low molecular weight heparins (VLMWHs) in the treatment of chronic ulcers, particularly of diabetic foot ulcers, and more specifically in the manufacture of a medicinal product for the treatment of chronic ulcers, and particularly diabetic foot ulcers and pressure ulcers.

An improved method for preparing a composition including a heparinoid, a local anesthetic, and a buffer for treatment of a lower urinary tract disease or condition can comprise either: (A) (i) providing a heparinoid in solid form or liquid form; (ii) providing a local anesthetic in solid form or liquid form; (iii) adding a liquid buffer to the heparinoid in solid form or liquid form; (iv) adding the local anesthetic to the mixture of the liquid buffer and the heparinoid; and (v) if necessary, adjusting the pH of the mixture of the liquid buffer, the local anesthetic, and the heparinoid so that a pH is achieved of from about 6.8 to about 8.3 is achieved without precipitation of the local anesthetic; or (B) (i)providing a heparinoid in solid form or liquid form; (ii) providing a local anesthetic in solid form or liquid form; (iii) mixing the heparinoid in solid form or liquid form and the local anesthetic in solid form or liquid form; (iv) adding a liquid buffer to the mixture of the heparinoid and the local anesthetic to form a mixture of liquid buffer, the heparinoid, and the local anesthetic; and (v) if necessary, adjusting the pH of the mixture of the liquid buffer, the local anesthetic, and the heparinoid so that a pH is achieved of from about 7.0 to about 7.8 is achieved without precipitation of the local anesthetic. The invention also encompasses a stable premixed liquid composition that avoids precipitation of the local anesthetic.

The invention discloses a hydrogel dressing capable of effectively accelerating the repair and the regeneration of a wound surface, and a preparation method and application of the hydrogel dressing. The preparation method for the hydrogel dressing comprises the following steps of: S1: carrying out raw material preparation: adding a multi-sulfydryl compound and multi-arm polyethylene glycol of which the end group is a double bond into PBS (Phosphate Buffer Saline), and evenly stirring to obtain a hydrogel preliminary liquid; and S2: adding heparin and a bFGF (basic fibroblast growth factor) into the hydrogel solution, stirring, standing until no liquid flows, and preparing the heparin-bFGF hydrogel dressing. The prepared heparin-bFGF hydrogel dressing guarantees that the heparin and the bFGF are stably slowly released within time longer than 10 days, and the heparin-bFGF hydrogel dressing is applied to wound surface healing of chronic wound surface ulcers caused by diabetes mellitus, vascular diseases, infection and the like. The heparin-bFGF hydrogel dressing disclosed by the invention has the advantages that the exogenous bFGF is effectively slowly released on a wound surface andthe wound surface healing of the chronic wound surface ulcers is accelerated.

The invention relates to a local application emplastrum with analgesic activity and simultaneously capability of enabling hematoma reabsorption, which comprises a basal layer, a pharmaceutically acceptable diclofenac salt, a hydrogel matrix form adhesion layer with heparin or heparitin, and a protective membrane capable of being removed in use.

Provided herein is a scaffold comprising a decellularized meniscus tissue, wherein the scaffold is covalently conjugated with heparin and a growth factor. Also provided herein is a method of repairingand / or treating a tissue injury in a subject in need thereof, comprising: providing a scaffold comprising a decellularized meniscus tissue; and repairing and / or treating the tissue injury by implanting the scaffold over the tear, wherein the scaffold is covalently conjugated with heparin and a growth factor.

The invention provides a woven reinforced degradable polyurethane elastomer artificial blood vessel and a preparation method thereof. The inner layer of the artificial blood vessel adopts activated H2N-PEG-COOH, heparin and (Mpa)-GGGGGREDV polypeptide to treat a C-PEEUU-NH2 electrospun nanofiber tubular stent to obtain a C-PEEUU-PEG-Hep / REDV tubular stent, the middle layer adopts a woven reinforced layer of nanofiber yarns woven by dissolving and mixing one or more master batches of PLGA, PDO and PGA according to a mass ratio, and the outer layer is a macroporous layer prepared by thermally induced phase separation. The woven reinforced degradable polyurethane elastomer artificial blood vessel provided by the invention can be used for tissue regeneration and construction of cardiovascularand cerebrovascular diseases, the preparation method is simple and efficient, the price is low, and the prepared artificial blood vessel has resilience, compliance, bursting strength and biocompatibility matched with autologous vascular tissues. The artificial blood vessel has no hypersensitivity to a human body in a transplantation operation, has affinity with blood and peripheral tissues in thehuman body, and has a good application prospect in repair operations of cardiology surgery, nephrology surgery and brain surgery.

Disclosed herein are cellular derived heparin and heparan sulfate compositions, methods of making and using, and cell lines for making and using.

The invention discloses a purifying column, device and method for purifying blood. An inner cavity of a columnar container in the purifying column is divided into a first space and a second space through a semipermeable membrane; agglutinin or a mixture formed by mixing heparin and agglutinin according to a preset proportion is treated as an adsorption medium to coat a solid substrate, and then the solid substrate is transferred into dialysate; the dialysate containing the adsorption medium flows in the same direction as blood in the first space and in the second space, and therefore the adsorption medium can effectively adsorb substances to be adsorbed (such as pathogens and tumor secretory protein) in the blood through the semipermeable membrane; and meanwhile, due to the fact that the dialysate containing the adsorption medium dynamically flows in the second space, after the dialysate is used for a long time and the adsorption medium loses efficacy, a dialysis column does not need to be replaced, and medical resources are saved.

The invention relates to a urethral catheter and a preparation method thereof. The urethral catheter comprises a catheter body, a coating formed on the surface of the catheter body, and heparin and chitosan which are self-assembled on the outer surface of the coating layer by layer, wherein the coating is formed by a coating composition, and the coating composition comprises at least one photocurable polymer. According to the urethral catheter, the damage of the urethral catheter to the inner surface of the urethra can be avoided. Meanwhile, accumulation of crystals can be effectively inhibited, bacteria adhered to the surface of the urethral catheter and the wound surface of the urethra can be killed, and the risk of bacterial infection is reduced.

The present invention relates to locking compositions, kits containing the locking compositions and methods for maintaining the patency of vascular access devices or intravascular delivery devices employing the locking compositions. The locking compositions contain water, an anticoagulant and a viscosity agent and are free of heparin and alcohol.

The invention relates to a urinary catheter and a preparation method thereof. The urinary catheter of the invention comprises: a tube body, a coating formed on the surface of the tube body, and heparin and heparin that are self-assembled layer by layer on the outer surface of the coating Chitosan, the coating is formed from a coating composition comprising at least one photocurable polymer. The urinary catheter of the present invention can prevent the catheter from damaging the inner surface of the urethra. At the same time, it can effectively inhibit the accumulation of crystals and kill the bacteria adhering to the surface of the catheter and the wound of the urethra, reducing the risk of bacterial infection.

The invention discloses a method for separating and analyzing derivatized heparan sulfate disaccharides containing free amino groups. The functional relationship between the mass of the disaccharides and the peak area detected by mass spectrometry can be used for the quantification of heparin and heparan sulfate disaccharides in actual biological samples detection. The invention can detect heparin and heparan sulfate disaccharides in liquid phase-mass spectrometry analysis, especially the heparan sulfate disaccharides containing free amino groups, and can also be separated by conventional liquid chromatography and analyzed in combination with ultraviolet and fluorescence detectors. This has an important role in the study of clinical drugs heparin, heparan sulfate, heparin derivatives and disaccharide components of various biological samples.

Isolated heparin or heparan sulphate oligosaccharide fragments having a chain length of at least 10 saccharides and no more than 50 saccharides, which are capable of binding BMP2, are disclosed. Also disclosed is the use of the same heparin or heparan sulphate oligosaccharide fragments in kits and pharmaceutical compositions, and the use of the same heparan sulphate oligosaccharide fragments in the repair and / or regeneration of connective tissue and bones, and the treatment of wounds.

The invention discloses bacillus subtilis engineering bacteria expressing recombinant flavobacteriun heparinum heparinase I, wherein the class name is bacillus subtilis which is preserved in the CGMCC (China General Microbiological Culture Collection Center) of CCCCM (China Committee for Culture Collection of Microorganisms) on 15th February, 2012, with preservation number CGMCC No.5757. A construction method comprises the following steps: transferring the coding gene of the flavobacteriun heparinum heparinase I into the bacillus subtilis WB600 to obtain the engineering bacteria capable of secreting and expressing heparinase. The bacillus subtilis engineering bacterial disclosed by the invention can stably and efficiently express the recombinant heparinase I; and the heparinase I can specifically degrade heparin and heparan glucosidic bond, and can be applied to the industrial production of low-molecular heparin, research of heparin and clinical medicine.

The invention discloses a hydrogel dressing that can effectively promote wound repair and regeneration, and its preparation method and application. The preparation method includes the following steps: S1 Prepare raw materials: polymercapto compound and multi-armed polyethylene glycol with double bonds as end groups Alcohol was added to the PBS buffer solution, and after stirring evenly, the hydrogel pre-liquid was obtained; S2, heparin and bFGF were added to the hydrogel solution, stirred, and left to stand until no liquid flowed, and the heparin-bFGF hydrogel dressing was prepared. The prepared heparin-bFGF hydrogel dressing ensures the stable and sustained release of heparin and bFGF for more than 10 days; the heparin-bFGF hydrogel dressing is applied to the wound healing of chronic wound ulcers caused by diabetes, vascular disease, infection, etc. . The heparin-bFGF hydrogel dressing of the present invention has the advantages of effectively slow-releasing exogenous bFGF at the wound and promoting wound healing of chronic wound ulcer.